Clinical Trial Update: Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CD19-specific CAR-engineered autologous T cells for relapsed or refractory CD19-positive acute lymphoblastic leukemia; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR-T cells (autologous) (CD19-specific chimeric antigen receptor T cells)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-30